 Anixa Biosciences Inc NASDAQ: ANIX shares drop after the FDA has requested additional information on its Chimeric Antigen Receptor-T cell therapy CAR-T being developed in partnership with Moffitt Cancer Center MCC. The study under the Investigational New Drug IND application has been placed on clinical hold pending submission of additional information requested by the FDA. 